Effect of oral administration of CpG ODN-OVA on WBB6F1-W/Wv mice.
BACKGROUND
We have already reported that antigen-specific IgG1 antibody production in WBB6F1-W/Wv (W/Wv) mice after oral administration of ovalbumin (OVA) was extremely high. Active systemic anaphylaxis (ASA) was induced in these mice after intraperitoneal (i.p.) administration of OVA, and Th2-dominant helper T-cell activation occurred. In this study, we examined the effect of CpG oligodeoxynucleotide (ODN) conjugation of OVA on oral immunization of W/Wv mice.


METHODS
W/Wv mice were sensitized by administration of 0.1 mg OVA or CpG ODN-OVA by gavage every day for 4 weeks, and the serum titers of OVA-specific IgG1, IgE, and IgG2a antibody were determined. ASA was induced by i.p. injection of OVA, and the changes in body temperature were monitored. In vitro production of Th1- and Th2- type cytokines by splenocytes re-stimulated with antigen was also measured.


RESULTS
The antigen-specific IgG1 antibody titer in the CpG ODN-OVA-sensitized W/Wv mice was lower than in the OVA-sensitized group, but the IgG2a titer was higher. ASA was not induced by i.p. OVA challenge. There were significant increases in the production of Th1-type cytokine (IFN-gamma) by splenocytes in the CpG ODN-OVA-sensitized mice, but the Th2-type cytokine (IL-4) level in the splenocyte culture medium was lower.


CONCLUSIONS
These results indicated that oral administration of CpG ODN-OVA conjugate significantly induced antigen-specific Th1 responses and reduced Th2 responses (allergic reactions) on re-stimulation. These findings suggest that CpG ODN-antigen conjugate may be useful as an oral vaccine.
Teshima
Reiko
R
Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Tokyo, Japan. rteshima@nihs.go.jp
Okunuki
Haruyo
H
Sato
Yuji
Y
Akiyama
Hiroshi
H
Maitani
Tamio
T
Sawada
Jun-ichi
J
D000284:Administration, Oral; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005512:Food Hypersensitivity / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007136:Immunoglobulins / Q000032:analysis; D051379:Mice; D023421:Models, Animal; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000276:immunology / Q000494:pharmacology; D010047:Ovalbumin / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000276:immunology / Q000494:pharmacology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
C516146:CpG ODN-OVA; D016207:Cytokines; D007074:Immunoglobulin G; D007136:Immunoglobulins; D009838:Oligodeoxyribonucleotides; D019444:Vaccines, DNA; D010047:Ovalbumin